Compare IPAR & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPAR | ACAD |
|---|---|---|
| Founded | 1982 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.3B |
| IPO Year | 1995 | 2000 |
| Metric | IPAR | ACAD |
|---|---|---|
| Price | $116.81 | $28.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 22 |
| Target Price | ★ $116.60 | $30.55 |
| AVG Volume (30 Days) | 228.7K | ★ 1.7M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | 2.34 | ★ 69.12 |
| EPS | ★ 2.31 | 0.20 |
| Revenue | ★ $1,317,700,000.00 | $726,437,000.00 |
| Revenue This Year | $3.86 | $18.80 |
| Revenue Next Year | $7.89 | $11.70 |
| P/E Ratio | ★ $50.84 | $144.55 |
| Revenue Growth | 21.26 | ★ 40.45 |
| 52 Week Low | $77.21 | $19.69 |
| 52 Week High | $129.29 | $30.96 |
| Indicator | IPAR | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 48.09 | 53.08 |
| Support Level | $115.59 | $27.90 |
| Resistance Level | $124.64 | $30.96 |
| Average True Range (ATR) | 3.51 | 0.86 |
| MACD | -0.08 | -0.23 |
| Stochastic Oscillator | 61.30 | 29.41 |
Interparfums Inc operates in the fragrance business and produces and distributes a wide array of prestige fragrance and fragrance-related products. It sells its product under the brand which includes Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lacoste, Lanvin, Moncler, Montblanc, Rochas and Van Cleef & Arpels. The company operates in two operating segments namely European based operations, SA, and United States based operations. The group sells its products to department stores, perfumeries, specialty stores, and domestic and international wholesalers and distributors.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.